Comparative Pharmacology
Head-to-head clinical analysis: ATROPEN versus PAMINE FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPEN versus PAMINE FORTE.
ATROPEN vs PAMINE FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5). Blocks parasympathetic nerve impulses, leading to increased heart rate, bronchodilation, decreased secretions, and mydriasis.
Anticholinergic agent; competitively blocks acetylcholine at muscarinic receptors, reducing gastrointestinal motility and secretory activity.
0.5 to 1 mg IV/IM/SC every 3 to 5 minutes as needed; maximum 3 mg total. For bradycardia: 0.5 mg IV every 3-5 minutes to a maximum of 3 mg. For organophosphate poisoning: 2 mg IV/IM initially, then 2 mg every 5-10 minutes until atropinization.
1 tablet (5 mg) orally 4 times daily, before meals and at bedtime.
None Documented
None Documented
Terminal half-life ~2-3 hours in adults; prolonged in elderly and infants due to reduced clearance.
1.5-2 hours; prolonged in renal impairment
Renal: ~50% unchanged; hepatic metabolism (hydrolysis) accounts for ~30-40%; fecal: <5%.
Renal (70% unchanged), biliary/fecal (30%)
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent